Imfinzi
Payments companies reported to CMS as associated with Imfinzi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Imfinzi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Imfinzi
These are the largest totals companies reported as associated with Imfinzi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $196,357.72 |
| Stephen Chun | Houston, TX | Radiation Oncology | $172,115.95 |
| Amit Mahipal | Rochester, MN | Medical Oncology | $162,578.56 |
| Michael Morse | Durham, NC | Hematology & Oncology | $149,775.32 |
| Hatim Husain | San Diego, CA | Internal Medicine | $141,621.99 |
| Beth Sandy | Philadelphia, PA | Adult Health (Nurse Practitioner) | $141,565.73 |
| Mohammed Al Hallak | Detroit, MI | Hematology & Oncology | $140,572.18 |
| Max Rosen | Worcester, MA | Diagnostic Radiology | $110,380.00 |
| Mohamed Salem | Charlotte, NC | Medical Oncology | $105,877.81 |
| Mohammadbagher Ziari | Corona, CA | Hematology & Oncology | $94,889.11 |
Prescribed Imfinzi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.